Epsilogen
Epsilogen develops pan-isotype antibody therapeutics, specifically focusing on IgE, IgA, and IgG-based molecules for the treatment of solid tumors. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is currently in phase Ib clinical trials for patients with platinum-resistant ovarian cancer. The company's platforms also include bispecific IgE and IgEG molecules designed to enhance immune responses within the tumor micro-environment.
Visit websiteHammersmith, UK
Biotechnology
Oncology
Life Sciences
Healthtech
Funding summary
- Total raised
- €36.9M
- Funding rounds
- 1
Investors in Epsilogen
Investors on record for Epsilogen. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Epsilogen?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors